At Loyola Medicine, we’re working to ease those fears with an innovative, incision-free treatment option called ...

Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate cancer,” said Ryan Rhodes, ...

A groundbreaking treatment for prostate cancer now available in Virginia aims to improve patient outcomes while minimizing side effects associated with traditional surgeries and radiation therapies.

Edap TMS SA (EDAP) reports robust HIFU revenue growth and strategic advancements, despite facing operational challenges and a ...

Q4 2024 Earnings Call Transcript March 27, 2025 EDAP TMS S.A. beats earnings expectations. Reported EPS is $-0.05, ...

“Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate cancer,” said Ryan ...

“Our strong fourth quarter performance reflects our continued progress in establishing Focal One Robotic HIFU as a mainstream treatment option for the management of prostate ...

As a reminder, the HIFI study is the first perspective, multi-center, non-inferiority comparative study evaluating HIFU and radical prostatectomy in the management of localized prostate cancer as ...